Companies:

 

Articles:

 
Biotech

Orthocell’s Remplir nerve repair technology sees first surgical use in US procedure

Go to Colin Hay author's page
By Colin Hay - 
Orthocell OCC ASX First Surgical Use Nerve Repair Remplir
Copied

Regenerative medicine company Orthocell (ASX: OCC) has achieved a major breakthrough in the global development of its Remplir technology with the successful completion of a first surgery in the US.

Doctors at a hospital in Ohio used the company’s trademarked nerve repair product in a surgical procedure to repair a foot injury.

Remplir, developed for peripheral nerve reconstruction, only recently gained clearance for use in the US—a market with an estimated value of $2.4 billion.

Significant milestone

“This first US surgery is a significant milestone for Orthocell and for the roll-out of Remplir in the US,” chief executive officer Paul Anderson said.

“It signals the start of our commercial journey in the world’s largest healthcare and nerve repair markets and reflects our commitment to delivering innovative, clinically proven solutions to surgeons and their patients.”

“A critical first step in the US starts with getting Remplir into surgeons’ hands for them to gain familiarity with its key features and benefits in clinical practice—these early cases play an important broader strategic role in building experience and knowledge amongst the surgical community.”

“We are confident our efforts in the US are on track to drive material growth in sales of Remplir during the second half of calendar 2025,” Mr Anderson added.

Specialist distributors

Orthocell appointed 14 specialist distributors in April 2025 to drive adoption across key regions, with the first surgery resulting directly from a distributor’s relationship with a nerve repair surgeon in Ohio.

Manufactured in Orthocell’s facility in Perth, Remplir is a collagen wrap for use in nerve repair surgery to improve regeneration of damaged nerves and patient outcomes.

Orthocell estimates the global nerve repair market is worth more than $5.3b, with around 2 million peripheral nerve repairs performed.

With approximately A$30 million cash at bank and no debt, the company is in an excellent position to broaden its commercial footprint and grow revenues in existing and new markets.